REFERENCES
1. Oh JH, Jun DW. The latest global burden of liver cancer: a past and present threat. Clin Mol Hepatol. 2023;29:355-7.
2. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335-47.
3. Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72:250-61.
4. Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014;60:110-7.
5. Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14:124-31.e1.
6. Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236.
7. Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922-65.
8. Singal AG, El-Serag HB. Rational HCC screening approaches for patients with NAFLD. J Hepatol. 2022;76:195-201.
9. Samoylova ML, Mehta N, Roberts JP, Yao FY. Predictors of ultrasound failure to detect hepatocellular carcinoma. Liver Transpl. 2018;24:1171-7.
10. An JY, Peña MA, Cunha GM, et al. Abbreviated MRI for hepatocellular carcinoma screening and surveillance. Radiographics. 2020;40:1916-31.
11. Kim DH, Yoon JH, Choi MH, et al. Comparison of non-contrast abbreviated MRI and ultrasound as surveillance modalities for HCC. J Hepatol. 2024;81:461-70.
12. Gupta P, Soundararajan R, Patel A, Kumar-M P, Sharma V, Kalra N. Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis. J Hepatol. 2021;75:108-19.
13. Huang DQ, Fowler KJ, Liau J, et al. Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: a prospective study. Aliment Pharmacol Ther. 2022;55:820-7.
14. Soundararajan R, Pooja AB, Gupta P, et al. Diagnostic performance of abbreviated MRI for HCC detection in patients with non-alcoholic fatty liver disease. J Clin Exp Hepatol. 2024;14:101276.
15. Best J, Bechmann LP, Sowa JP, et al. GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2020;18:728-35.e4.
16. Cerrito L, Mignini I, Ainora ME, Mosoni C, Gasbarrini A, Zocco MA. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: the prognostic role of liver stiffness measurement. Cancers. 2023;15:637.
17. Cannella R, Dioguardi Burgio M, Sartoris R, Gregory J, Vilgrain V, Ronot M. Adherence to LI-RADS and EASL high-risk population criteria: a systematic review. Hepatology. 2023;77:1958-67.
18. Cannella R, Zins M, Brancatelli G. ESR Essentials: diagnosis of hepatocellular carcinoma-practice recommendations by ESGAR. Eur Radiol. 2024;34:2127-39.
19. CT/MRI LI-RADS® v2018 CORE. Available from: https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-2018-Core.pdf. [Last accessed on 18 Dec 2024].
20. Ludwig DR, Fraum TJ, Cannella R, et al. Expanding the liver imaging reporting and data system (LI-RADS) v2018 diagnostic population: performance and reliability of LI-RADS for distinguishing hepatocellular carcinoma (HCC) from non-HCC primary liver carcinoma in patients who do not meet strict LI-RADS high-risk criteria. HPB. 2019;21:1697-706.
21. Fraum TJ, Cannella R, Ludwig DR, et al. Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors. Eur Radiol. 2020;30:996-1007.
22. Kim DH, Choi SH, Kim DW, et al. Combined hepatocellular-cholangiocarcinoma: magnetic resonance imaging features and prognosis according to risk factors for hepatocellular carcinoma. J Magn Reson Imaging. 2021;53:1803-12.
23. Desai A, Sandhu S, Lai JP, Sandhu DS. Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review. World J Hepatol. 2019;11:1-18.
24. Di Martino M, Saba L, Bosco S, et al. Hepatocellular carcinoma (HCC) in non-cirrhotic liver: clinical, radiological and pathological findings. Eur Radiol. 2014;24:1446-54.
25. Gaddikeri S, McNeeley MF, Wang CL, et al. Hepatocellular carcinoma in the noncirrhotic liver. AJR Am J Roentgenol. 2014;203:W34-47.
26. Mamone G, Di Piazza A, Carollo V, et al. Imaging of primary malignant tumors in non-cirrhotic liver. Diagn Interv Imaging. 2020;101:519-35.
27. Winston CB, Schwartz LH, Fong Y, Blumgart LH, Panicek DM. Hepatocellular carcinoma: MR imaging findings in cirrhotic livers and noncirrhotic livers. Radiology. 1999;210:75-9.
28. Lafitte M, Laurent V, Soyer P, et al. MDCT features of hepatocellular carcinoma (HCC) in non-cirrhotic liver. Diagn Interv Imaging. 2016;97:355-60.
29. Brancatelli G, Federle MP, Grazioli L, Carr BI. Hepatocellular carcinoma in noncirrhotic liver: CT, clinical, and pathologic findings in 39 U.S. residents. Radiology. 2002;222:89-94.
30. Park EJ, Son JH, Choi SH. Imaging features of hepatocellular carcinoma in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: a systematic review and meta-analysis. Abdom Radiol. 2022;47:2089-98.
31. Cannella R, Ronot M, Sartoris R, et al. Enhancing capsule in hepatocellular carcinoma: intra-individual comparison between CT and MRI with extracellular contrast agent. Diagn Interv Imaging. 2021;102:735-42.
32. Thompson SM, Garg I, Ehman EC, et al. Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI. Br J Radiol. 2018;91:20180345.
33. WHO Classification of Tumours Editorial Board. Digestive system tumours. Available from: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Digestive-System-Tumours-2019. [Last accessed on 18 Dec 2024].
34. Mulé S, Galletto Pregliasco A, Tenenhaus A, et al. Multiphase liver MRI for identifying the macrotrabecular-massive subtype of hepatocellular carcinoma. Radiology. 2020;295:562-71.
35. Salomao M, Yu WM, Brown RS Jr, Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol. 2010;34:1630-6.
36. Trapani L, Beaufrère A, Hobeika C, et al. Pathological overview of steatohepatitic hepatocellular carcinoma in a surgical series. Histopathology. 2023;83:526-37.
37. Yamaoka K, Saitoh S, Kinowaki K, et al. Clinicopathological assessment of steatohepatitic hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2022;46:101799.
38. Jain D, Nayak NC, Kumaran V, Saigal S. Steatohepatitic hepatocellular carcinoma, a morphologic indicator of associated metabolic risk factors: a study from India. Arch Pathol Lab Med. 2013;137:961-6.
39. Cannella R, Dioguardi Burgio M, Beaufrère A, et al. Imaging features of histological subtypes of hepatocellular carcinoma: implication for LI-RADS. JHEP Rep. 2021;3:100380.
40. Mulé S, Serhal A, Pregliasco AG, et al. MRI features associated with HCC histologic subtypes: a western American and European bicenter study. Eur Radiol. 2023;33:1342-52.
41. Auer TA, Halskov S, Fehrenbach U, et al. Gd-EOB MRI for HCC subtype differentiation in a western population according to the 5(th) edition of the World Health Organization classification. Eur Radiol. 2023;33:6902-15.
42. Inui S, Kondo H, Tanahashi Y, et al. Steatohepatitic hepatocellular carcinoma: imaging findings with clinicopathological correlation. Clin Radiol. 2021;76:160.e15-25.
43. Chen K, Xu Y, Dong Y, et al. Contrast-enhanced imaging features and clinicopathological investigation of steatohepatitic hepatocellular carcinoma. Diagnostics. 2023;13:1337.
44. Park JH, Park YN, Kim MJ, et al. Steatotic hepatocellular carcinoma: association of MRI findings to underlying liver disease and clinicopathological characteristics. Liver Int. 2023;43:1332-44.
45. Faure A, Dioguardi Burgio M, Cannella R, et al. Imaging and prognostic characterization of fat-containing hepatocellular carcinoma subtypes. Radiol Med. 2024;129:687-701.
46. Tan DJH, Ng CH, Lin SY, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022;23:521-30.
47. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681-93.
48. American College of RadiologyTM. Liver imaging reporting & data system (LI-RADS®). Available from: https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Reporting-and-Data-Systems/LI-RADS. [Last accessed on 24 Apr 2025].
49. Nguyen N, Rode A, Trillaud H, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma developed on non-alcoholic fatty liver disease. Liver Int. 2022;42:905-17.
50. Koh YX, Tan HJ, Liew YX, et al. Liver resection for nonalcoholic fatty liver disease-associated hepatocellular carcinoma. J Am Coll Surg. 2019;229:467-78.e1.
51. Cauchy F, Zalinski S, Dokmak S, et al. Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome. Br J Surg. 2013;100:113-21.
52. Chin KM, Prieto M, Cheong CK, et al. Outcomes after curative therapy for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: a meta-analysis and review of current literature. HPB. 2021;23:1164-74.
53. Younossi Z, Stepanova M, Ong JP, et al; Global Nonalcoholic Steatohepatitis Council. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol 2019;17:748-55.e3.
54. Burgio M, Garzelli L, Cannella R, Ronot M, Vilgrain V. Hepatocellular carcinoma: optimal radiological evaluation before liver transplantation. Life. 2023;13:2267.
55. Wong CR, Njei B, Nguyen MH, Nguyen A, Lim JK. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017;46:1061-9.
56. Reddy SK, Steel JL, Chen HW, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology. 2012;55:1809-19.
57. Haldar D, Kern B, Hodson J, et al; European Liver and Intestine Transplant Association (ELITA). Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European liver transplant registry study. J Hepatol 2019;71:313-22.
58. Foerster F, Gairing SJ, Müller L, Galle PR. NAFLD-driven HCC: safety and efficacy of current and emerging treatment options. J Hepatol. 2022;76:446-57.
59. Pfister D, Núñez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:450-6.
60. Pal Chaudhary S, Reyes S, Chase ML, et al. Resection of NAFLD/NASH-related hepatocellular carcinoma (HCC): clinical features and outcomes compared with HCC due to other etiologies. Oncologist. 2023;28:341-50.
61. Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62:1723-30.
62. Molinari M, Kaltenmeier C, Samra PB, et al. Hepatic resection for hepatocellular carcinoma in nonalcoholic fatty liver disease: a systematic review and meta-analysis of 7226 patients. Ann Surg Open. 2021;2:e065.
63. Koh B, Danpanichkul P, Wang M, Tan DJH, Ng CH. Application of artificial intelligence in the diagnosis of hepatocellular carcinoma. egastro. 2023;1:e100002.
64. Okanoue T, Yamaguchi K, Shima T, et al. Artificial intelligence/neural network system that accurately diagnoses hepatocellular carcinoma in nonalcoholic steatohepatitis. Hepatol Res. 2023;53:1213-23.
65. Sarkar S, Alurwar A, Ly C, et al. A machine learning model to predict risk for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease. Gastro Hep Adv. 2024;3:498-505.
66. Kawka M, Dawidziuk A, Jiao LR, Gall TMH. Artificial intelligence in the detection, characterisation and prediction of hepatocellular carcinoma: a narrative review. Transl Gastroenterol Hepatol. 2022;7:41.
67. Ghosh S, Zhao X, Alim M, Brudno M, Bhat M. Artificial intelligence applied to 'omics data in liver disease: towards a personalised approach for diagnosis, prognosis and treatment. Gut. 2025;74:295-311.
